Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Is Bezlotoxumab Effective, Tolerable and Cost Saving in Preventing Recurrent Clostridium Difficile Infections in Patients With Malignancies? An Exploratory Study

NCT04415918 is registered in ClinicalTrials.gov with The Cooper Health System as lead sponsor.

NCT NCT04415918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04415918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Is Bezlotoxumab Effective, Tolerable and Cost Saving in Preventing Recurrent Clostridium Difficile Infections in Patients With Malignancies? An Exploratory Study
Lead sponsor
The Cooper Health System
Phase
Phase 4
Overall status
Unknown status
Start date
July 1, 2020
Completion date
December 31, 2021
Enrollment
132 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection recurrence